MedTrace Logo

Chemotherapy Plus Donor White Blood Cell Infusion in Treating Patients With Relapsed Hematologic Cancer Following Donor Peripheral Stem Cell Transplantation

NCT00005946 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2019-10-17

No results posted yet for this study

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. White blood cells from donors may be able to prevent graft-versus-host disease in patients with hematologic cancer that has relapsed following donor peripheral stem cell transplantation.

PURPOSE: Phase I trial to study the effectiveness of chemotherapy plus donor white blood cell infusion in treating patients who have relapsed hematologic cancer following donor peripheral stem cell transplantation.

Conditions

Interventions

BIOLOGICAL

filgrastim

BIOLOGICAL

therapeutic allogeneic lymphocytes

DRUG

cyclophosphamide

DRUG

etoposide

Sponsors & Collaborators

  • University of Maryland, Baltimore

    lead OTHER

Principal Investigators

  • Bijoyesh Mookerjee, MD · Jefferson Medical College of Thomas Jefferson University

Study Design

Purpose
TREATMENT

Eligibility

Max Age
120 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2000-10-31
Primary Completion
2002-06-30
Completion
2002-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00005946 on ClinicalTrials.gov